Literature DB >> 7146823

Improvement of some blood coagulation factors in cirrhotic patients treated with low doses of heparin.

C Cordova, A Musca, F Violi, C Alessandri, E Vezza.   

Abstract

Effects of subcutaneous calcium-heparin and vitamin K administration were studied in 30 cirrhotic patients showing low values of prothrombin time, antithrombin III, fibrinogen, platelet count, plasminogen, alpha 2-antiplasmin, raised levels of fibrin(ogen) degradation products and prolonged activated partial thromboplastin time. A group of 10 patients was first treated with K vitamin for 15 d; after vitamin K therapy interruption, a treatment with 5000 IU (8000 IU in 1 patient) every 12 h of subcutaneous calcium-heparin was started. In another group of 20 patients a treatment with 5000 IU (8000 IU in 2 patients) every 12 h of subcutaneous calcium-heparin was started immediately. The heparin administration in both groups had been performed for at least 2 weeks. No significant changes of blood coagulation picture were observed after vitamin K administration, while calcium-heparin treatment showed an increase in prothrombin time, fibrinogen, platelet count, plasminogen, alpha 2-antiplasmin, a decrease in fibrin(ogen) degradation products and a shortened activated partial thromboplastin time. There was no significant change in antithrombin III values.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7146823     DOI: 10.1111/j.1600-0609.1982.tb00588.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  3 in total

Review 1.  Haemostatic problems in liver disease.

Authors:  D A Kelly; E G Tuddenham
Journal:  Gut       Date:  1986-03       Impact factor: 23.059

2.  Antithrombin III metabolism in patients with liver disease.

Authors:  E Knot; J W Ten Cate; H R Drijfhout; L H Kahlé; G N Tytgat
Journal:  J Clin Pathol       Date:  1984-05       Impact factor: 3.411

3.  Antithrombin III, plasminogen and alpha 2 antiplasmin in jaundice. Clinical usefulness and prognostic significance.

Authors:  J J Rodzynek; D Urbain; P Leautaud; P Wettendorff; A Delcourt
Journal:  Gut       Date:  1984-10       Impact factor: 23.059

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.